SEMINAR
Monday, March 17th, 2025
Graduate Studies Amphitheater, Μedical School, University of Crete
Time: 10:00am
“B cell and antibody immune responses:
their significance in the design of monoclonal antibodies for cancer therapy”
Prof. Sophia Karagiannis
Translational Cancer Immunology and Immunotherapy
King’s College London
Virtual link: https://uoc-gr.zoom.us/j/89775541355?pwd=M26x9IMV2a4zw2c3r7QUaUMwdmaaiy.1
Meeting ID: 897 7554 1355
Passcode: 118085
Short Biograph: Sophia Karagiannis is a translational cancer immunologist specializing in antibody therapies for melanoma, ovarian and breast carcinomas. Gained BA and MS degrees at Rutgers University, USA, having received scholarship awards and a teaching assistantship (1987, 1991). PhD was awarded at King’s College London in Biochemistry under SERC and SmithKline Beecham-funded scholarships (1995). Subsequently developed immunotherapeutic strategies for cancer and inflammatory diseases in academic and biotechnology environments in London and Cambridge as a postdoctoral associate and scientific investigator and formed a research group as a NIHR/BRC Senior Research Fellow in 2007. The Karagiannis team at King’s College London is presently focused on dissecting humoral immunity in cancer and elucidating tumor-targeting and immune effector activating mechanisms of IgE and IgG antibodies.
Co-founded and co-chairs the International Task Force on AllergoOncology and has pioneered IgE therapeutics for solid tumors. Her research and development initiative on the first IgE class antibody for cancer therapy is conducted in close collaboration with clinical and academic groups at King’s College London and the CR-UL Drug Development Office.